Invictus MD Strategies (Invictus MD Strategies) ROCE % : -27.37% (As of Oct. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Invictus MD Strategies's annualized ROCE % for the quarter that ended in Oct. 2019 was -27.37%.

Invictus MD Strategies ROCE % Historical Data

The historical data trend for Invictus MD Strategies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies ROCE % Chart

Invictus MD Strategies Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

ROCE %

-100.00

0.33

-51.81

-31.86

-27.92

Invictus MD Strategies Quarterly Data
	Jan15	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19
ROCE %	Get a 7-Day Free Trial															-34.81	-42.98	-13.16	-22.21	-27.37

Invictus MD Strategies ROCE % Calculation

Invictus MD Strategies's annualized ROCE % for the fiscal year that ended in Jan. 2019 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jan. 2019 )		(A: Jan. 2018 )		(A: Jan. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jan. 2019 )		(A: Jan. 2018 )		(A: Jan. 2019 )
	=	-27.902	/	( ( (92.885 - 2.077)	+	(115.72 - 6.63) )	/ 2 )
	=	-27.902	/	( (90.808	+	109.09)	/ 2 )
	=	-27.902	/	99.949
	=	-27.92 %

Invictus MD Strategies's ROCE % of for the quarter that ended in Oct. 2019 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2019 )		(Q: Jul. 2019 )		(Q: Oct. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2019 )		(Q: Jul. 2019 )		(Q: Oct. 2019 )
	=	-24.5	/	( ( (99.928 - 6.032)	+	(94.687 - 9.525) )	/ 2 )
	=	-24.5	/	( ( 93.896	+	85.162 )	/ 2 )
	=	-24.5	/	89.529
	=	-27.37 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2019) EBIT data.

Invictus MD Strategies (OTCPK:IVITF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Invictus MD Strategies ROCE % Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.